Veloxis increases share capital in connection with exercise of warrants

Udgivet den 30-05-2016  |  kl. 08:00  |  

Company Announcement no. 11/2016

 

To: NASDAQ OMX Copenhagen A/S                                          Hørsholm, Denmark, 30 May 2016

  

 

Veloxis increases share capital in connection with exercise of warrants

 

Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 1,871,906 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 187,190.60 as a consequence of the exercise of warrants by current and former employees of the company granted under the company's warrant program.

 

As a result of the employee's investment in the company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 1,114,509

 

The subscription prices for the new shares are as follows (per share of nominal DKK 0.10):

 

1,195,000 shares DKK 0.35

116,820 shares DKK 0.95

140,509 shares DKK 1.03

419,577 shares DKK 1.05

 

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 168,737,844.70 divided into shares of DKK 0.10 each.

 

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

  

For more information, please contact:

 

Craig A. Collard                                        

President & CEO                                       

Phone: +1 919 524 4317                          

Email: cac@veloxis.com                            

  

Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

 

Vedhæftede filer:

300516 Veloxis Announces Exercise of Warrants.pdf

Udgivet af: NPinvestordk

Seneste nyheder

11:08 Aktier/BofA: Europæisk marked har haft største kapitalstrømning i over et år denne uge
11:04 Eurozonens inflation bekræftet i endelig opgørelse
09:28 Danske Bank dropper salgsanbefaling af Zealand Pharma og siger nu "hold"
09:13 Aktier/åbning: Bavarian og Mærsk topper og sender C25 op for niende dag i streg
09:08 Mærsk tager endnu en uge med gevaldigt hop i vigtigt rateindeks
08:49 Obligationer/åbning: Renterne kravler opad fra start efter amerikansk vending
08:38 Cartier-ejer slog salgsforventninger - ny direktør skal drive fremtidig vækst
08:26 Aktier/tendens: Rockwool og Bavarian i fokus - vinderstime kan blive brudt
08:15 Danske Bank skruer op for TCM's kursmål efter "bedre end ventet start" på året
07:53 De kinesiske myndigheder giver boligkøbere en hjælpende hånd
07:34 Råvarer: Oliepriserne stiger på grund af tegn på stigende efterspørgsel
07:27 Obligationer/tendens: Inflationsdata under lup - renterne ses stige lidt fra start
07:19 ABG siger nu "køb" til Rockwool efter regnskab
06:45 JPMorgan hæver Rockwools kursmål og kommer lige over den aktuelle aktiekurs
06:41 Asien: Wall Street-fald trækker asiatiske aktier med ned
06:35 Asiatiske rederier ligger blandet fredag med plusser i Japan
06:35 ISS får kursmålet sat op af Jefferies med 14 pct.
06:34 USA frygter stigning i mpox - med ny farlig variant i Afrika
06:34 Kinas industriproduktion viser positive takter men detailsalget skuffer lidt i april
06:32 Valuta: Dollar står til største ugentlige svækkelse i flere måneder